利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.055 秒)

    Combination of levobunolol and dipivefrin for topical ophthalmic use
    31.
    发明授权
    Combination of levobunolol and dipivefrin for topical ophthalmic use 失效
    左布洛尔和dipiffrin的组合用于局部眼用

    公开(公告)号：US5733938A

    公开(公告)日：1998-03-31

    申请号：US303850

    申请日：1994-09-09

    申请人： Orest Olejnik ,  Gary D. Novack

    发明人： Orest Olejnik ,  Gary D. Novack

    IPC分类号： A61K31/222 ,  A61K31/135

    CPC分类号： A61K31/222 ,  Y10S514/913

    摘要： Disclosed are pharmaceutical compositions comprising dipivefrin and levobunolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    摘要翻译： 公开了包含用于局部眼科递送的dipiferfrin和左布洛尔的药物组合物，以及一种治疗方法，包括当指定用于青光眼的时候施用所述组合物和相关的病症，例如在人眼中升高的眼内压。

    Ketaneserinol as an agent to reduce intraocular pressure
    32.
    发明授权
    Ketaneserinol as an agent to reduce intraocular pressure 失效
    氯胺酮作为降低眼内压的药物

    公开(公告)号：US5290781A

    公开(公告)日：1994-03-01

    申请号：US954

    申请日：1993-01-05

    申请人： Ramon L. Espino ,  Donald G. Musson ,  Orest Olejnik

    发明人： Ramon L. Espino ,  Donald G. Musson ,  Orest Olejnik

    IPC分类号： A61K31/505

    CPC分类号： A61K31/505 ,  Y10S514/913

    摘要： This invention relates to the use of ketanserinol as an ophthalmic therapeutic agent to reduce intraocular pressure and its method of use for treating glaucoma by systemic administration of ketanserinol, it salts, esters or prodrugs to a patient or more particularly, topically administering ketanserinol and salts thereof to the eye of a patient.

    摘要翻译： 本发明涉及作为眼科治疗剂的氯苯那醇作为眼内压降低的用途及其用于治疗青光眼的方法，其通过向患者全身施用酮乃烯醇，其盐，酯或前药，或更特别地，局部给予氯苯那醇及其盐 到患者的眼睛。

    CYCLOSPORIN COMPOSITIONS
    36.
    发明申请
    CYCLOSPORIN COMPOSITIONS 有权
    环磷酰胺组合物

    公开(公告)号：US20120270805A1

    公开(公告)日：2012-10-25

    申请号：US13536479

    申请日：2012-06-28

    申请人： JAMES N. CHANG ,  Orest Olejnik ,  Bruce A. Firestone

    发明人： JAMES N. CHANG ,  Orest Olejnik ,  Bruce A. Firestone

    IPC分类号： A61K38/13 ,  A61P27/02

    CPC分类号： A61K38/13 ,  A61K9/0048 ,  A61K9/107 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44

    摘要： A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.

    摘要翻译： 本文公开了一种组合物，其包含约0.001％至约0.4％的环孢菌素A，蓖麻油和选自醇乙氧基化物，醇，烷基糖苷，烷基多糖苷，烷基酚乙氧基化物，氧化胺，嵌段聚合物，羧化的 醇或烷基酚乙氧基化物，羧酸/脂肪酸，纤维素衍生物，乙氧基化醇，乙氧基化烷基酚，乙氧基化芳基酚，乙氧基化脂肪酸，乙氧基化脂肪酸，乙氧基化脂肪酯和油，脂肪醇，脂肪酯，二醇酯，羊毛脂基 衍生物，卵磷脂和卵磷脂衍生物，木质素和木质素衍生物，甲酯，单酸甘油酯和衍生物，磷脂，聚丙烯酸，聚乙二醇，聚环氧乙烷 - 聚氧丙烯共聚物，聚环氧乙烷，聚合物表面活性剂，聚环氧丙烷，丙氧基化醇，丙氧基化烷基酚， 丙氧基化脂肪酸，基于蛋白质的surfa 硅藻土衍生物，硅氧烷基表面活性剂，脱水山梨糖醇衍生物，硬脂酸盐，蔗糖和葡萄糖酯及其衍生物及其组合。

    DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG
    37.
    发明申请
    DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG 审中-公开
    将活性药物递送到眼睛的后期部分，通过PRODRUG的分支或全面递送

    公开(公告)号：US20120157499A1

    公开(公告)日：2012-06-21

    申请号：US13407906

    申请日：2012-02-29

    申请人： Patrick M. Hughes ,  Orest Olejnik

    发明人： Patrick M. Hughes ,  Orest Olejnik

    IPC分类号： A61K31/4436 ,  A61P37/08 ,  A61P35/00 ,  A61P27/02 ,  A61K31/23

    CPC分类号： A61K31/557 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/203

    摘要： The present invention relates to method of sustained-delivery of an active drug to a posterior part of an eye of a mammal to treat or prevent a disease or condition affecting said mammal, wherein said disease or condition can be treated or prevented by the action of said active drug upon said posterior part of the eye, comprising administering an effective amount of an ester prodrug of the active drug subconjunctivally or periocularly. Preferably, the active drug is more than about 10 times as active as the prodrug. Other aspects of this invention deal with the treatment of certain diseases by the periocular or subconjunctival delivery of an ester prodrug, and certain pharmaceutical products containing ester prodrugs for periocular or subconjunctival administration.

    摘要翻译： 本发明涉及将活性药物持续递送至哺乳动物眼睛的后部以治疗或预防影响所述哺乳动物的疾病或病症的方法，其中所述疾病或病症可以通过以下作用来治疗或预防： 所述活性药物在眼睛的所述后部，包括给予有效量的活性药物的结膜下或眼下的酯前药。 优选地，活性药物的活性大于前药的约10倍。 本发明的其它方面涉及通过酯前药的眼周或结膜下递送治疗某些疾病，以及含有用于眼周或结膜下给药的酯前药的某些药物产品。

    PHARMACEUTICAL COMPOSITIONS CONTAINING PROPIONIC PRESERVATIVE COMPONENTS
    38.
    发明申请
    PHARMACEUTICAL COMPOSITIONS CONTAINING PROPIONIC PRESERVATIVE COMPONENTS 审中-公开
    含有特殊防腐组分的药物组合物

    公开(公告)号：US20100331430A1

    公开(公告)日：2010-12-30

    申请号：US12824387

    申请日：2010-06-28

    申请人： Orest Olejnik

    发明人： Orest Olejnik

    IPC分类号： A61K47/12 ,  A61P27/02

    CPC分类号： A61K9/0048 ,  A61K9/08

    摘要： The invention provides ophthalmic compositions preserved using propionic preservative components alone or in combination with at least one additional preservative. In particular, an improvement in anti-microbial activity against bacteria is seen in addition to activity specific to fungal organisms and/or mold.

    摘要翻译： 本发明提供使用丙酸防腐剂组分单独或与至少一种另外的防腐剂组合保存的眼用组合物。 特别地，除了对真菌生物体和/或霉菌特异性的活性之外，还观察到针对细菌的抗微生物活性的改善。

    STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS
    39.
    发明申请
    STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS 有权
    稳定的生物可降解神经毒素植入物

    公开(公告)号：US20100068244A1

    公开(公告)日：2010-03-18

    申请号：US12577114

    申请日：2009-10-09

    申请人： Patrick M. Hughes ,  Orest Olejnik

    发明人： Patrick M. Hughes ,  Orest Olejnik

    IPC分类号： A61K9/00 ,  A61K39/08 ,  A61K39/02 ,  A61P37/04 ,  A61P31/08

    CPC分类号： A61K9/0024 ,  A61K9/0051 ,  A61K9/204 ,  A61K38/4893

    摘要： Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.

    摘要翻译： 提供了可生物降解的神经毒素植入物和制造和使用这种植入物的方法。 可生物降解的神经毒素植入物包括神经毒素，可生物降解的聚合物组分和酸度调节组分。 当植入物位于患者体内时，可生物降解的聚合物组分有效地控制来自植入物的神经毒素的释放。 酸性调节组分有效地将植入物的pH保持在期望的范围内，当植入物位于患者体内时，当植入物生物降解时，稳定神经毒素是有效的。 在一个实施方案中，植入物包括肉毒杆菌毒素，可生物降解聚合物，以及衍生生物可降解聚合物的单体或包含单体单元的寡聚物，所述单体基本上与衍生可生物降解聚合物的单体相同，或这些单体和 低聚物。 低聚物和可生物降解的聚合物可以衍生自单一类型的单体。 本文公开的植入物可以施用于需要长时间治疗效果的人或动物患者。